Possible first treatment for metastatic pancreatic cancer coming to the Netherlands
A new medication called Rasonque has received a positive recommendation for the treatment of metastatic pancreatic cancer, potentially offering a more effective alternative to chemotherapy. Clinical trial results showed that the drug can extend patient survival and delay disease progression, with final European and Dutch regulatory decisions regarding market access and reimbursement pending.
A potential new treatment for patients with metastatic pancreatic cancer, known as Rasonque, has received a positive recommendation from the European Medicines Agency. The drug, which contains the active ingredient daraxonrasib and is produced by the American firm Revolution Medicines, aims to extend the lives of patients for whom traditional chemotherapy is ineffective. Clinical trials involving five hundred participants indicated that those taking the tablets lived for over a year on average, significantly longer than the seven-month survival rate typically associated with standard chemotherapy. Additionally, the medication was shown to delay the progression of the disease for a longer period.
Currently, approximately 3,300 people are diagnosed with pancreatic cancer in the Netherlands each year, with many cases already in advanced stages at the time of diagnosis. The European Commission must still grant final approval for the drug before it can enter the market. Following that, the Dutch Healthcare Institute will assess whether the treatment should be covered by the national healthcare system.
Based on reporting by ad. Translated and condensed by LocalHeadlines.
